Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website athttp://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until August 14, 2009.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certai
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... New and more complex medicines ... manufacturers, payers, pharmacists and patients. Now Specialty Pharmacy ... partnering with the National Association of Specialty Pharmacy ... to this developing field to better equip pharmacy ... , “This partnership creates a powerful platform for ...
(Date:4/28/2015)... 28, 2015 Celebrating women has become a ... be the third year that all things mom and female ... Hands On is offering some great specials Special ... of the year could there be to focus on woman," ... pampering and this is a terrific time for it. And ...
(Date:4/28/2015)... 28, 2015 SeniorCare.com has published the ... the reality problem Americans have regarding aging and long-term ... long-term care services as they age, 63% of Americans ... , In the report, Carol Marak of SeniorCare.com interviewed ... American Health Care Association and The Scan Foundation. The ...
(Date:4/28/2015)... Once considered an unproven alternative to HID lighting, the ... storm with perfectly tailored light spectrums in an ideal, low ... than half of every SuperCloset and SuperRoom sold are now ... is gone and LED Grow Lights are here to stay. ... their first hand experience using the new LED Grow lights ...
(Date:4/28/2015)... The west coast, south, east coast, ... areas that healthcare professionals searched for jobs through the ... of March 2015. Data was released by the ... jobs , physical therapy jobs , and other ... health fields. , States with the most ...
Breaking Medicine News(10 mins):Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 2Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 3Health News:Specialty Pharmacy Times Partners with National Association of Specialty Pharmacy to Improve Care for Patients 4Health News:Commack Massage Therapy and Wellness Day Spa Dedicates Time To Celebrate Women 2Health News:SeniorCare.com Report: America Has a Major Misconception on Aging 2Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:Hot States for Medical Careers: Healthcare Staffing Agency Aureus Medical Releases Online Search Results 2
... genetic factors and drug abuse saying that genetic tendencies play ... ,Dr. Kenneth S. Kendler, who has led the ... the importance of genetic factors in a culture/country (Norway) with ... that in such countries, social rather than genetics factors should ...
... When the body's arteries, veins and capillaries become diseased, ... the possibility of stroke and heart attack.// Dennis Gable, ... Baylor Regional Medical Center at Plano, provides information about ... ,Varicose veins: ,Varicose veins are large, twisted, swollen ...
... person dying of coronary heart disease can be predicted by ... venules in the eyes. ,Arterioles and venules are ... reflects the general state of the smaller blood vessels in ... of the study, 78 women (just over 4%) and 114 ...
... be a wake up call to get the duvets washed and ... their duvets even in six months, and these could// be the ... ,A survey conducted in many households revealed that two ... months. The dust mites and filth are potential health hazards ...
... have said one therapeutic dose of radiation resulted in mice ... ,Research in US have indicated, in a study ... Physiology that mice that has received a single therapeutic dose ... of radiation received by human cancer patients lost as much ...
... NHS has launched National Transplant Week to raise awareness of ... take place and the number of people// awaiting transplants. ... population in Britain has joined the Organ Donor Register. In ... on transplant lists, only 2,200 actually operations took place. ...
Cached Medicine News:Health News:Vascular Disease 101: Discovering and Treating Common Diseases of the Veins 2Health News:National Transplant Week to Raise Need for Organ Donation 2
(Date:4/28/2015)... 2015  Shares of Celladon Corp. (NASDAQ: CLDN ... the announcement of poor drug trial results of the phase ... agent, MYDICAR.  The selloff may be warranted or it ... bargain basement prices. An analyst report update ... pipeline, financial review, analyst summary, valuation, and recommendation can ...
(Date:4/28/2015)... Israel , April 28, 2015 ... in its sixth funding cycle for U.S.- Israel ... and Energy Efficiency. To be considered, a project ... between a company and a university/research institution (one from the ... proposal should have significant commercial potential and the project outcome ...
(Date:4/27/2015)... Techpool Bio-Pharma Co has experienced tremendous changes in ... chief executive officer, transforming from a traditional private Chinese company ... took office in 2011, he was the senior executive ... and Eisai, with more than 20 years successful management experience ... Asia-Pacific region. "I chose Techpool ...
Breaking Medicine Technology:Examining what's Left after MYDICAR Drug Trial Ends In Failure; Celladon Corp. Analyst Report Issued by BrokerBank Securities, Inc. 2Opportunities for Funding U.S.-Israel Cooperation for Renewable Energy and Efficiency 2Techpool Transforms Into International Player 2Techpool Transforms Into International Player 3
... 9, 2011 NeurogesX, Inc. (Nasdaq: NGSX ... novel pain management therapies, today announced it will hold ... p.m. ET (1:30 p.m. PT) to provide an update ... patch for the management of neuropathic pain associated with ...
... Misonix, Inc. (Nasdaq: MSON ), ... markets innovative, therapeutic, ultrasonic products worldwide for wound ... surgical and medical applications, today reported financial results ... ending December 31, 2010.  Michael A. McManus Jr., ...
Cached Medicine Technology:NeurogesX to Provide Qutenza® Launch Update 2NeurogesX to Provide Qutenza® Launch Update 3NeurogesX to Provide Qutenza® Launch Update 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 2Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 3Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 4Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 5Misonix Reports Second Quarter and Six Months Fiscal 2011 Financial Results 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: